FindTrial
Sign In

Investigation of incidence of gastric cancer identified after Helicobacter pylori eradication using Vonoprazan: large prospective cohort study.

Investigation of incidence of gastric cancer identified after Helicobacter pylori eradication using Vonoprazan: large prospective cohort study. - Incidence of gastric cancer after eradication using Vonoprazan

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000021384
Enrollment
Unknown
Registered
2016-03-07
Start date
2016-02-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic gastritis caused by Helicobacter pylori infection

Interventions

None listed

Sponsors

NTT Medical Center Tokyo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with Helicobacter pylori infection Willingness to provide informed consent.

Exclusion criteria

Exclusion criteria: Patients judged as inappropriate candidates for the trial by the investigators

Design outcomes

Primary

MeasureTime frame
Incidence rate of gastric cancer—

Secondary

MeasureTime frame
Changes of endoscopic findings (atrophy, gastroduodenal injury, relux esophagitis, Barrett's esophagus)—

Countries

Japan

Contacts

Public ContactYoshitsugu Misumi

NTT Medical Center Tokyo Gastroenterology

yoshikft34@gmail.com03-3448-6547

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026